TP53 and non-small cell lung carcinoma: For instance, some studies reported that p53 over-expression increases chemosensitivity to platinum drugs in NSCLC patients,[11] whereas some other studies reported that p53 over expression decreases chemosensitivity to platinum drugs.[12] Meanwhile, several other studies suggested that p53 protein abnormality does not affect chemosensitivity to platinum drugs.[13] Because of differences in experimental methods, sample size, and inconsistency in the research population, it is difficult to generalize the results of a single sample to the entire population.